Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

Substance P free acid is a Sensory neuropeptide and inflammatory mediator. Exerts excitatory effects on central and peripheral neurons, constricts bronchioles and is involved in pain transmission.

Substance P antagonists (SPA).

SU5614 is a potent and selective FLT3 inhibitor.

SU5402（SU-5402; SU5402） is potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor. (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively).

SU11274 is a selective Met inhibitor with IC50 of 10 nM.

SU 5214 is a modulator of tyrosine kinase signal transduction.

STO-609 is a selective, cell-permeable inhibitor of Ca2+-calmodulin-dependent protein kinase kinase (Ki values are 80 and 15 ng/ml for inhibition of CaM-KKα and CaM-KKβ respectively); competes for the ATP-binding site.

STK16-IN-1 is a STK16 kinase inhibitor with an IC50 of 295 nM.

STING inhibitor C-178 is a covalent, small-molecule inhibitor of STING, blocks palmitoylation (PMA)-induced clustering of STING; covalently binds to Cys91, directly targets mouse STING (mmSTING) but not human STING (hsSTING).

STING inhibitor C-178 is a covalent, in vivo-active, small-molecule inhibitor of STING

STF-083010 is a specific IRE1α endonuclease inhibitor.

StemRegenin 1 antagonizes hematopoietic stem cell differentiation.

STD1T (USP2a inhibitor STD1T) is a hit-to-lead, small-molecule inhibitor of USP2a with IC50 of 3.3 uM in Ub-AMC assays, displays no activity against USP7 at 10 uM.

Staurosporine is a prototypical potent ATP-competitive kinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively.

Stattic, the first nonpeptidic small molecule, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM, highly selectivity over STAT1.

Stat5 Inhibitor is a cell permeable nonpetidic nicotinoyl hydrazone which suppresses Stat5 via binding to the SH2 domain.

SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.

SRT2104 (GSK2245840) is a selective SIRT1 activator involved in the regulation of energy homeostasis. Phase 2.

SRT1720 is a selective SIRT1 activator with EC50 of 0.16 μM, but is >230-fold less potent for SIRT2 and SIRT3.

SRT1720 is a selective activator of human SIRT1 (EC1.5 = 0.16 μM) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 μM；SIRT3: EC1.5 > 300 μM).

SRPIN340 is a selective SRPK inhibitor with Ki of 0.89 μM for SRPK1, showing no significant inhibitory activity against more than 140 other kinases..

SR9243 is a new inhibitor of The nuclear receptor liver-X-receptor (LXR),inducing LXR-corepressor interaction.

SR9011 is a REV-ERBα/β agonist with IC50s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.

SR9009 is an agonist of REV-ERB with IC50 = 670 nM for REV-ERBα and IC50 = 800 nM for REV-ERBβ.

SR-3677 is a new potent and selective ROCK-II inhibitor with an IC50 of ~3 nM in enzyme and cell based assays; IC50 for ROCK-I is 56 ± 12 nM.

SR3335 (ML-176) is a selective RORα synthetic ligand, directly binds to RORα, but not other RORs, and functions as a selective partial inverse agonist of RORα in cell-based assays.

SR-12813 is a pregnane X receptor (PXR) agonist.

SR 8278 is the first synthetic antagonist of the nuclear heme receptor Rev-ErbA, inhibits the REV-ERBα transcriptional repression activity with EC50 of 0.47 uM in HEK293 cells..